# Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

> **NCT05322499** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Stage IV Esophagus Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel
- **DRUG:** Paclitaxel-albumin
- **DRUG:** Docetaxel
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT05322499
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-15
- **Primary completion:** 2023-04-15
- **Final completion:** 2025-04-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322499, "Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05322499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*